Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
124.51
+2.10 (1.72%)
Oct 11, 2024, 4:00 PM EDT - Market closed
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,314 employees as of December 31, 2023. The number of employees increased by 152 or 13.08% compared to the previous year.
Employees
1,314
Change (1Y)
152
Growth (1Y)
13.08%
Revenue / Employee
$1,145,352
Profits / Employee
$35,995
Market Cap
11.87B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Solventum | 20,098 |
Smith & Nephew | 19,081 |
Catalent | 17,800 |
Teleflex | 14,500 |
Medpace Holdings | 5,900 |
Bio-Techne | 3,050 |
Neurocrine Biosciences | 1,400 |
SRPT News
- 11 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 16 days ago - Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - Business Wire
- 23 days ago - Sarepta Therapeutics Muscles Up In DMD Race - Seeking Alpha
- 26 days ago - Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors - Business Wire
- 5 weeks ago - Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year - Business Wire
- 6 weeks ago - Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire
- 2 months ago - Biotech Stock Flashing Bull Signal - Forbes
- 2 months ago - Sarepta Therapeutics, Inc. (SRPT) Q2 2024 Earnings Call Transcript - Seeking Alpha